Skip to main content
Equibles
VTGN logo

VTGN · Vistagen Therapeutics, Inc.

Track VTGN — free

Use VTGN with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about VTGN

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.27 +0.00 (+0.49%) At close · Aug 14
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As of August 14, 2026, the issuance date of the condensed consolidated financial statements as of and for the three months ended June 30, 2026, there is uncertainty about whether the Company's combined cash, cash equivalents, and marketable securities will be sufficient to fund operations beyond twelve months from the issuance date of these condensed consolidated financial statements and therefore the Company concluded that substantial doubt exists about its ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$11.88M
Shares
44.38M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.27 Open$0.27 Day$0.26–0.27 52W close$0.23–4.90 Avg vol 30d5.4M Short int2.0M · 4.5% float · 2.4d Short vol66% Last earningsJun 30, 2026 DataJun 2023–Aug 2026 Filing10-Q · Aug 14

Raw chart and full-history price indicators begin at the captured split on Jun 7, 2023; bars on opposite sides are not compared.

Up next

Next earnings call
Oct 3, 2026 Est · unconfirmed · in 7 wks
FQ2-27 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 14, 2026

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bearish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −77%
below
Price vs 50-day avg −29%
below
RSI (14) 44
neutral
MACD trend Positive
52-week position 1%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +16%
trailing
6-month return −51%
trailing
YTD return −59%
this year
Relative strength −65%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Distributing
-5% holders QoQ · +9 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
4.52% of float · ▲ +25.7% MoM · 2.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
54 holders — mid 3-yr range
Squeeze score 64
elevated · 0–100
Fundamentals
Weak
Revenue growth −120%
Y/Y
EPS growth −10%
Y/Y
Free cash flow $-66.6M
Balance sheet $32.3M
net cash
Quant / Vol
risk profile
Very High
Volatility 133%
annualized · 1-yr
Max drawdown −95%
past year
ATR 10.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−77% Bearish
Price vs 50-day avg
−29% Bearish
RSI (14)
44 Neutral
MACD trend
Positive Bullish
52-week position
1% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Distributing
-5% holders QoQ · +9 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
4.52% of float · ▲ +25.7% MoM · 2.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
54 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 1% Range high $5
vs 200-day avg -77% vs 50-day avg -29%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
VTGN
Vistagen Therapeutics, Inc.
this stock
$11.88M -59.5% -120.5% — 4.5%
ONC
BeOne Medicines Ltd.
 $513.62B +14.4% +22179.2% 789.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.19B +11.6% +46.2% 29.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.72B +4.1% +20.8% 19.9 3.3%
ARGX
Argenx SE
 $52.94B +1.2% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
54
% held
29.4%
Net QoQ
-2.3M sh
Top holder
Commodore Capital LP
Held Float
View
Held by Funds
Fund positions
14
View
Short & Settlement
Short Interest Rising
Shares short
2.0M
Days to cover
2.4d
Change
+409.6K sh
View
Short Volume
Short vol %
66%
As of
Aug 14, 2026
Short Total
View
Fails to Deliver
FTD shares
1.0K
Value
$250
As of
Jul 10, 2026
View
Off-Exchange
Off-exchange %
61.5%
Week of
Jul 6, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$-227.0K
Net income (FY)
$-69.7M
EPS diluted
$-1.83
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 14, 2026
This year
25
View
Exempt Offerings
Offering
$2.8M
Filed
Feb 21, 2023
View
Earnings & Events
Earnings Calls
Last call
Jun 30, 2026
View

Performance

Raw-price comparisons begin at the captured split on Jun 7, 2023; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
VTGN -7.0% +16.4% -51.4% +11.0% -59.5%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY -7.4% +11.9% -65.1% +7.1% -73.3%
Key facts CIK 1411685 CUSIP 92840H400 13F (30d) 57 filings 56 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)